Floatz logo

Dabrafenib

Tumor Skin

TriHealth Inc.Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Tumor Skin cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
Rapamycin
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
TACROLIMUS
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Cancer Research UK
Phase 2/3B
Nivolumab
UNICANCER
Phase 2B

View all 24 →

Same molecule, other indications

Dabrafenib is also rated in:

cutaneous melanomaDormant
BB
Indicative ·
66 / 100
View asset →
melanomaDormant
BB
Indicative ·
66 / 100
View asset →
melanomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →